Skip to main content

    Main navigation

    • Investors
    • About
    • News
    • Contact us
    • Egoo.health
    • en
    • sv
Home

Main navigation

  • Investors
  • About
  • News
  • Contact us
  • Egoo.health
  • en
  • sv
 

Investors

+

Main navigation

Main navigation

  • News - Press releases
  • Financial Calendar
  • Financial reports
    • IPO and listning documents
  • Corporate governance
    • Articles Of Association
    • AGM and Extraordinary general meetings
      • General meeting on 5 May 2021
      • Extraordinary Shareholders Meeting 19 November
      • Extraordinary general meeting January 2020
      • Annual General Meeting, May 20, 2020
    • Auditor
    • Election committee
    • Certified adviser
  • Share information
    • Major shareholders
    • Sharecapital
    • Incentive programme
    • Dividend Policy
    • Warrants (TO)
  • Board
  • Management
  • Insiders
  • IR Contact
  • Presentations
regulatory
2021-04-12 08:00
Qlife publishes Annual report 2020

The report can be downloaded from the website or ordered via the company; info@Egoo.health.

regulatory
2021-03-31 20:16
Correction: Notice of annual general meeting in Qlife Holding AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

regulatory
2021-03-31 08:15
Notice of annual general meeting in Qlife Holding AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

regulatory
2021-03-31 08:00
The Nomination Committee’s proposals for new board members in Qlife

Qlife’s Nomination Committee proposes that the Annual General Meeting elects Mette-Marie Harild, Ulrik Harrysson and Mikael Persson as new Board members.

regulatory
2021-02-18 10:00
QLIFE HOLDING AB YEAR END REPORT 2020, Q4

FINANCIAL SUMMARY - FOURTH QUARTER 2020

not regulatory
2021-01-29 08:00
Qlife receives order from Statens Serum Institut for COVID-19 testing

“It is of great importance for Qlife to get a significant order from a highly professional customer directly after the CE-marking.

not regulatory
2021-01-25 08:00
Qlife granted its first patent for Egoo.Health device

The Danish Patent Office has granted Qlife patent number DK180348 B1 for its biomarker detection unit.

not regulatory
2021-01-07 08:00
Qlife CE-marks COVID-19 test

The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market.

regulatory
2020-12-22 10:59
Qlife raises loans of SEK 15 million to strengthen working capital ahead of the upcoming market launch.

Qlife expects to CE mark its COVID-19 test for professional use in the Egoo.Health system within short.

not regulatory
2020-11-30 08:00
Qlife to increase decentralized testing of professional football in Denmark with Divisionsforeningen - Egoo.Health-platform placed in three clubs

Since May 2020, Qlife has been handling all testing for COVID-19 for professional football in Denmark.

not regulatory
2020-11-27 13:57
Qlife will not respond to preliminary rejection by the Danish Medicines Agency for COVID-19 test – focus on receiving CE-marking by year-end

On November 13, Qlife was informed that the Danish Medicines Agency (Lægemiddelstyrelsen) had rejected the application for temporay approval in Denmark “in the interest of health protection” for th

not regulatory
2020-11-24 08:45
Qlife receives order for COVID-19 tests to European Women’s Handball Championship 2020

”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high preci

regulatory
2020-11-19 11:30
Bulletin from the extraordinary shareholders’ meeting in Qlife Holding AB

Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants

regulatory
2020-11-18 11:44
QLIFE HOLDING AB INTERIM REPORT Q3, 2020

FINANCIAL SUMMARY - THIRD QUARTER 2020

regulatory
2020-11-13 17:55
Qlife: application for temporary approval in Denmark "in the interest of health protection" receives preliminary rejection by the Danish Medicines Agency

In parallel to the ongoing process of preparing and putting together the dossier for the CE-mark, Qlife has submitted an application for placing the product on the market at this stage, as it offer

not regulatory
2020-11-03 09:03
Nomination Committee appointed for Qlife Holding's Annual General Meeting 2021

The Nomination Committee consists of the following persons, who together represent approximately 39 percent of the company's shares and votes.

regulatory
2020-11-02 08:30
Notice of extraordinary shareholders’ meeting in Qlife Holding AB

Information regarding the coronavirus

regulatory
2020-10-30 12:00
Qlife CE-mark for COVID-19 test delayed 2-3 months – application for temporary approval in Denmark due to public health interest submitted

Qlife was originally expecting CE-mark for the product in October, but the company is now expecting approval within the coming two to three months.

not regulatory
2020-08-21 13:55
Qlife to expand their COVID-19 testing to include all professional handball in Denmark

Due to the increasing of infectious rates over the past few weeks, it has been agreed that Qlife will be handling all testing for COVID-19 for professional handball in Denmark.

regulatory
2020-08-18 09:45
QLIFE HOLDING AB INTERIM REPORT Q2, 2020

FINANCIAL SUMMARY – SECOND QUARTER 2020

not regulatory
2020-07-30 15:14
Qlife extends contract with Divisionsforeningen

In cooperation with KMD, Qlife has extended the contract with Divisionsforeningen.

not regulatory
2020-07-17 15:52
Qlife continues to work with professional sports, now abroad and within cycling

Qlife's focus on professional sports is centered around COVID-19 testing, which the company offers in collaboration with IT partner KMD.

regulatory
2020-07-08 08:30
Qlife hires Jakob Broberg Lind as Sales Director Clinical

Jakob has extensive experience from international sales and business development within MedTech and healthcare and brings an excellent record of results and achievements in complex and competitive

not regulatory
2020-07-06 14:55
News letter - commercial activities and communication

In April we closed a contract with the professional Danish football league for regular testing of all players and staff for COVID-19 and delivery of test results were initiated already in week 22.

regulatory
2020-06-22 15:58
Henrik Ljung will take the role of Chief Financial Officer, CFO, in Qlife Holding AB.

"Henrik Ljung brings broad experience to Qlife from financial reporting, IR, business control, finance management and corporate governance, all with a focus on fast-growing companies in the ea

not regulatory
2020-06-19 19:53
Qlife tests badminton players for COVID-19, for this weekend's RSL Final 4 play

KMD and Qlife has entered an agreement with Badmint

not regulatory
2020-06-04 11:25
MOVING CLOSER TO THE MARKET - PROFESSIONAL SPORTS, CULTURE AND ENTERTAINMENT

Geelmuyden Kiese and KMD announced earlier today that they have entered a partnership to provide smart and efficient Covid-19 test solutions for the professional sports, culture, and entertainment

not regulatory
2020-06-02 10:27
Qlife to develop SARS-CoV-2 total antibody test

The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months.

regulatory
2020-05-20 14:00
Bulletin from the Annual General Meeting in Qlife Holding AB on May 20th, 2020

Resolution on adoption of accounts and allocation of the company’s result

regulatory
2020-05-20 08:15
Qlife Holding AB, Interim Report January – March 2020

FINANCIAL SUMMARY FIRST QUARTER 2020

regulatory
2020-05-12 16:35
Qlife has entered a first strategically important sales agreement for their COVID-19 test

The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga).

not regulatory
2020-04-22 10:55
Qlife enters agreement with Nordsjællands Hospital to start validation of COVID-19 test

Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test.

regulatory
2020-04-16 10:00
Notice of annual shareholders’ meeting in Qlife Holding AB

Information regarding the coronavirus

not regulatory
2020-04-03 15:50
Qlife updates on process for COVID-19 test

Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:

regulatory
2020-03-31 16:55
Qlife to expand the Egoo.Health platform with COVID-19 test through licence deal

Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.

not regulatory
2020-03-13 16:30
Corona virus, COVID-19, has limited impact on Qlife Holding AB

Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.

not regulatory
2020-03-02 08:45
Qlife commences trading on Nasdaq First North Growth Market

Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm.

not regulatory
2020-02-28 12:16
Qlife has been approved for listing on the Nasdaq First North Growth Market with first day of trading on March 2[nd,] 2020

The short name for the Company’s shares on Nasdaq First North is QLIFE. The short name for the TO1 series warrants is QLIFE TO1.

not regulatory
2020-01-29 12:30
Qlife announces CE-mark for professional use for its first biomarker capsule on the Egoo Home System.

The Egoo Home System is an integrated platform consisting of a small device, disposable capsules, each a test for a specific biomarker, and a digital infrastructure that can share data with patient

not regulatory
2019-11-28 10:37
New presentation from Stora Aktiedagen Stockholm on 25 Nov

CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Stockholm on 25 November.

not regulatory
2019-11-06 10:20
Presentation of Qlife on Stora Aktiedagen (Shareholder’s Day)

CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November.

not regulatory
2019-11-06 09:11
Top Danish politicians were excited when testing their own biomarkers with Egoo

The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier.

not regulatory
2019-10-31 14:18
Qlife is showcased by the Danish Minister of Health and the Minister for Industry

Qlife is showcased by the Danish Minister of Health and the Minister for Industry, Business and Financial Affairs for the launch of new public program for innovative purchasing of medical equipment

not regulatory
2019-10-16 16:20
Newsletter

In the enclosed Newsletter you will find updated information about our operations and preparations for the next steps.

not regulatory
2019-10-14 10:58
Soon, everybody can test their own blood at home

Biomarkers in our blood can show us a lot about our health, the development of a disease or how tough we have been to our body during a workout.

not regulatory
2019-10-14 10:53
Qlife speaks at the Healthcare IoT conference on 24 October – managing patient data a vital question for the future!

Every day, the Danish healthcare system produces a large amount of data.

not regulatory
2019-10-14 10:51
Qlife participates at Intrum Stockholm Open on 18 October 2019!

Six interesting companies in total will present their businesses.

Watch the video of the presentation

Qlife

Qlife Holding AB
Hamntorget 3
SE-252 21 Helsingborg, Sweden
info@egoo.health

Links

  • About
  • Investors
  • Egoo.health

Qlife’s vision is to facilitate regular blood biomarker testing from home environment. We aim to make blood sampling convenient, cheap, fast, accessible and accurate resulting in more frequent blood testing to gain insight into personal health, with increased possibility for earlier discovery of illnesses. Our product is an integrated platform consisting of a small home device, disposable capsules each a test for a specific biomarker, and a digital infrastructure that shares data with patient journal or hospital platform.